54 August / September 2019
‘undruggables.’ PharmaTimes. June 2019.
http://www.pharmatimes.com/ magazine/2019/june_2019/drugging_the_ undruggables.
10. Bentley University. Thirty years of innovation pays off as oligonucleotide therapeutics come to market. Medical Xpress. 25 January 2018. https://
medicalxpress.com/news/2018-01-years-
oligonucleotide-therapeutics.html.
11. J.M. Beierlein, L.M. McNamee, F.D. Ledley. As Technologies for Nucleotide Therapeutics Mature, Products Emerge. Mol Ther Nucleic Acids 9 (2017) 379–86.
12. Editorial. The commercial tipping point. Nat Biotech 35 (2017) 181.
13. M.A. Bower, M.G. Campana, M. Whitten, C.J. Edwards, H. Jones, E. Barrett, R. Cassidy, R.E. Nisbet, E.W. Hill, C.J. Howe, M. Binns. The cosmopolitan maternal heritage of the Thoroughbred racehorse breed shows a significant contribution from British and Irish native mares. Biol Lett 7 (2011) 316–20.
14. T. Tozaki, K. Karasawa, Y. Minamijima, H. Ishii, M. Kikuchi, H. Kakoi, K. Hirota, K. Kusano, S. Nagata. Detection of phosphorothioated (PS) oligonucleotides
in horse plasma using a product ion (m/z 94.9362) derived from the PS moiety for doping control. BMC Res Notes 11 (2018) 770–5.
15. Eckstein F. Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther 24 (2014) 374–87.
Author biography
Teruaki Tozaki PhD is the Technical Advisor at the Genetic Analysis Department, Laboratory of Racing Chemistry, Japan; Visiting Lecturer at the Showa University School of Medicine; and Visiting Professor of Veterinary Medicine at the Faculty of Applied Biological Sciences, Gifu University. Dr Tozaki is also a Sports Pharmacist.
Authors’ contributions
Conception and design: T. Tozaki, K. Karasawa
Experiment implementation and data collection: T. Tozaki, K. Karasawa, H. Ishii, Y. Minamijima
Manuscript content and review: T. Tozaki
Data collection and analysis supervision and study design support: M. Kikuchi, H. Kakoi, K. Hirota, K. Kusano, S. Nagata
Declaration of interest
This article was written with the support of SCIEX, a Danaher operating company and a global leader in the accurate quantification and characterisation of molecules.
www.sciex.com
Disclaimer For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to
https://sciex.com/diagnostics.
IVD-MKT-19-9983-A
Trademarks and/or registered trademarks mentioned herein are the property of AB Sciex Pte. Ltd., or their respective owners, in the United States and/or certain other countries.
AB SCIEX™ is being used under license. © 2019 DH Tech. Dev. Pte Ltd.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
